Related Experiment Video

Updated: Aug 10, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Advances in clinical trials for amyotrophic lateral sclerosis

Paul H Gordon1

  • 1Eleanor and Lou Gehrig MDA/ALS Research Center, Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA. Phg8@columbia.edu

Current Neurology and Neuroscience Reports
|January 29, 2005
PubMed

Insights

Amyotrophic lateral sclerosis (ALS) clinical trials are advancing, but effective treatments remain elusive. Researchers are refining trial designs to overcome challenges and find meaningful therapies for ALS patients.

Area of Science:

  • Neurology
  • Clinical Trials
  • Drug Development

Background:

  • Amyotrophic lateral sclerosis (ALS) lacks treatments that can reverse symptoms.
  • Riluzole is the only approved drug, offering only modest slowing of ALS progression.
  • Significant challenges persist in developing effective ALS therapies.

Purpose of the Study:

  • To review the evolution of clinical trial designs for ALS.
  • To discuss recent advancements and ongoing challenges in ALS clinical trials.
  • To highlight specific ALS trials from the past five years.

Main Methods:

  • Analysis of recent randomized placebo-controlled trials in ALS.
  • Discussion of methodological improvements in trial design.
  • Evaluation of challenges including animal models, outcome measures, and patient dropout rates.

Main Results:

  • Despite advancements, no new drug has demonstrated a truly meaningful effect in slowing ALS.
  • Clinical trial sophistication has grown, but significant hurdles remain.
  • Ongoing research focuses on optimizing trial design and outcome measures.

Conclusions:

  • Randomized placebo-controlled trials are crucial for ALS therapy development.
  • Further innovation in trial methodology is needed to accelerate the discovery of effective ALS treatments.
  • Addressing challenges in trial design is key to finding meaningful interventions for ALS.

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...